A few days ago, the People's Daily Health Client and the People's Daily Health Times grandly released the 14th Healthy China Forum series list, Yasheng Pharmaceutical-B (06855) won a double harvest, dr. Yang Dajun, chairman and CEO of the company, won the "Top Ten Pharmaceutical Industry Figures" award, and the company's original Class 1 new drug Nerick ® won the "Top Ten New Drugs (Domestic)" award, and both won the first place in the list in this field.
The Healthy China Forum is one of the earliest, most influential, highest quality and most authoritative conferences held in the mainland medical and health circles with the theme of "Healthy China", which has been held for 14 sessions so far, and has become a national high-end forum jointly participated by the party and the government at all levels, medical and health management institutions, medical circles, pharmaceutical circles, health circles and media circles. Among them, the selection and release of the annual series of lists has also become one of the highlights of the forum, attracting much attention and expectations.
Based on the purpose of health promotion, social responsibility and media stance, the list work of the 14th Healthy China Forum was launched on October 7, 2021, which lasted more than 7 months of work, and relevant working institutions such as the list advisory committee, academic committee, and list working group were established, and the selection criteria for each list were formulated. The list working group solicits opinions extensively through industry expert recommendation, industry interviews, data verification, etc., and forms a candidate list in accordance with the participation criteria. Subsequently, after the academic committee review, online public voting and other links, the results of the annual top ten pharmaceutical industry figures, top ten new drugs (domestic and international), top ten medical devices, top ten Internet + medical services and other series of list results were finally determined. The selection is committed to commending and paying tribute to the industry leaders who have made outstanding contributions to promoting the high-quality development of China's pharmaceutical industry and drug research and development innovation in 2021, showing the results of the accelerated development of domestic innovative drugs in recent years, which has a high degree of authority and impartiality, and also gives a considerable significance to the target.
Dr. Dajun Yang and Nerick ® were both selected, which is highly recognized by industry experts, scholars and media for ASUN Pharmaceutical's innovative R&D and clinical development capabilities.
According to the organizers, Dr. Yang Dajun led the company team to always adhere to the original innovation and globalization strategy, develop a number of international new original innovative drugs with "First-in-class" or "Best-in-class" potential, and constantly lead Chinese pharmaceutical companies to the world, and is one of the leaders of China's innovative pharmaceutical industry today.
As China's first and only approved third-generation BCR-ABL inhibitor, Nelik ® has broken the dilemma of Long-term Drug-free DRUG-Resistant CML patients with T315I mutations in China, filled the clinical gap, and showed the epitome of China's innovative drugs "from scratch, from have to excellent", marking that China's clinical strength in the field of hematology and tumors is gradually moving to the forefront of the world. As the world's second and China's first approved third-generation BCR-ABL inhibitor, Nerick ® has entered phase IB clinical trials for the treatment of drug-resistant CML in the United States, and has obtained 1 US Food and Drug Administration (FDA) fast-track qualification, 3 FDA orphan drug qualifications and 1 European Medicines Agency EU orphan drug qualification. Presenting the potential of a global "best-in-class" clinical progress since 2018, Nelik ® has been inducted into the Oral Presentation of the American Society of Hematology (ASH) Annual Meeting for four consecutive years and was nominated for "Best Research" at the 2019 ASH Annual Meeting.
Since being approved for listing in China in November last year, Nelik ® has been quickly included in the supplementary insurance or Huimin Insurance for major and exceptionally serious diseases in 5 provinces and 25 cities, and has entered the special drug list of 13 local Huimin Insurance. At the same time, the product has been clearly recommended by the Guidelines of the Chinese Society of Clinical Oncology (CSCO) and the Chinese Anti-Cancer Association's Guidelines for the Integrated Diagnosis and Treatment of Cancers (CACA). Nelik, China's original and world-leading innovative drug, is benefiting more and more patients. At present, Arison Pharma is actively conducting Clinical Trials of Nelik around the world and accelerating the needs of patients urgently needed in clinical practice around the world through the Designated Patient Drug Use Program (NPP).
Dr. Dajun Yang, Chairman and CEO of Yasheng Pharmaceutical, has been deeply involved in the fields of oncology, apoptosis mechanism and new drug research and development for nearly 30 years. Dr. Yang Dajun led Yasheng Pharmaceutical to always uphold the concept of "global innovation", efficiently promote the research and development progress and global layout of product pipelines, the company has 8 class 1 small molecule new drugs that have entered the clinical development stage, and is carrying out more than 50 Phase I/II clinical trials in China, the United States, Australia and Europe. Up to now, Asunc has been awarded 2 fast track and 2 pediatric rare disease qualifications by the US FDA, and has obtained a total of 16 US FDA and EU orphan drug qualifications, which continues to break the record of Chinese pharmaceutical companies and demonstrates the company's excellent global innovation ability and management level.